Expired activity
Please go to the PowerPak
homepage and select a course.
Severe Asthma Management: Addressing Emerging Evidence Regarding Phenotypes and Biomarkers
Provided by American Academy of CME, Inc.
Supported by an educational grant from Genentech, a member of the Roche Group.
Release date
May 30, 2020
Expiration date
May 30, 2021
Estimated time to complete activity
1.5 hours
Clinical Need
Asthma is a common respiratory disease in both adults and children. Severe or uncontrolled asthma significantly impacts a person’s health and quality of life. As the processes that drive asthma are better understood and targeted therapies are developed, patients with severe asthma have more options. When treatment is selected based upon patient-specific factors that can influence efficacy, clinical benefits and outcomes can be optimized.
As part of the interprofessional severe asthma healthcare team, pharmacists play a key role in educating their colleagues about new and emerging treatments for severe uncontrolled asthma and implications for patient care.
Faculty Educators
Suzanne G. Bollmeier, PharmD, FCCP, BCPS, AE-C
Professor, Pharmacy Practice
St. Louis College of Pharmacy
Clinical Pharmacist, South County Health Center
St Louis, Missouri
Target Audience
This activity has been developed for the pharmacist engaged in the care of patients with severe asthma. Other members of the care team may also participate.
Educational Objectives
After participating in this educational activity, learners should be better able to:
- Review the current state of severe asthma management, including emerging evidence regarding phenotypes and biomarkers, as well as mechanisms of action of approved and upcoming biologic therapies
- Analyze the role of the pharmacist in severe asthma management and barriers to achieving optimal asthma control in the pharmacy setting
- Evaluate strategies to increase both medication adherence and patient confidence in pharmacists as asthma management specialists
- Address the current issues and challenges for managed care in the treatment of severe asthma and formulate an action plan to alleviate these burdens
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. American Academy of CME, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacists
This activity provides 1.5 ACPE contact hours (0.15 CEUs) of continuing education credit. Universal Activity Number JA4008191-0000-20-006-H01-P, Application
Disclosure Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are able to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.
Faculty Educator
Suzanne G. Bollmeier, PharmD, FCCP, BCPS, AE-C
No relevant financial relationships with any commercial interests.
Planning Committee
John JD Juchniewicz, MCIS, CHCP, Edward Moylan, RPh, Wendy Gloffke, PhD and Paul Miniter, MS - No relevant financial relationships with any commercial interests.
Clinical Reviewer
Philip Coco, PharmD - No relevant financial relationships with any commercial interests.
This activity will review off-label or investigational information.
Disclaimer
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CPE credit for your participation, please complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately. For pharmacists, a statement of credit will be issued through CPE Monitor in 6-8 weeks. Only pharmacist learners who provided valid NABP e-Profile ID numbers and month and day of birth (MMDD) will be submitted to CPE Monitor for official record of credit.
Hardware/Software Requirements
Please ensure the computer you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5
Privacy
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm
Contact
For any questions, please contact: CEServices@academycme.org
Copyright
© 2020. This CPE-certified activity is held as copyrighted © by American Academy of CME, Inc. Through this notice, the Academy grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
